Open access

HIGHLIGHTS

  • who: Chemotherapy, and Reduces, Neoadjuvant from the therapeutic or surgical intervention (5)These challenges emphasize a critical need for new strategies to specifically target metastatic cancer cells, including , Department of Pathology and Molecular Medicine, Queen`s University, Kingston, Ontario, Canada. , Division of Cancer Biology and Genetics, Queen`s Cancer Research Institute have published the article: OPEN ACCESS, in the Journal: (JOURNAL) of 08/04/2023
  • what: The authors show that anti-ezrin treatment disease largely due to the development of resistance. In of anti-ezrin treatment in modulating response to in breast cancer cells as . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?